These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36878064)

  • 1. 2-Aminopyrimidine derivatives as selective dual inhibitors of JAK2 and FLT3 for the treatment of acute myeloid leukemia.
    Xu S; Zhu Y; Meng J; Li C; Zhu Z; Wang C; Gu YC; Han L; Wen J; Tong M; Shi X; Hou Y; Liu Y; Zhao Y
    Bioorg Chem; 2023 May; 134():106442. PubMed ID: 36878064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
    Li Y; Wang P; Chen C; Ye T; Han Y; Hou Y; Liu Y; Gong P; Qin M; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104361. PubMed ID: 33142418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3.
    Li Y; Ye T; Xu L; Dong Y; Luo Y; Wang C; Han Y; Chen K; Qin M; Liu Y; Zhao Y
    Eur J Med Chem; 2019 Nov; 181():111590. PubMed ID: 31408808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
    Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
    J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Potent and Selective FLT3 Inhibitor (
    Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
    J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.
    Xu Y; Wang NY; Song XJ; Lei Q; Ye TH; You XY; Zuo WQ; Xia Y; Zhang LD; Yu LT
    Bioorg Med Chem; 2015 Aug; 23(15):4333-4343. PubMed ID: 26142317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
    Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.
    Lian X; Gao Y; Li X; Wang P; Tong L; Li J; Zhou Y; Liu T
    Bioorg Med Chem Lett; 2023 Nov; 96():129519. PubMed ID: 37838343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
    Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
    Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
    Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
    Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia.
    Ran F; Liu Y; Zhu J; Deng X; Wu H; Tao W; Xie X; Hu Y; Zhang Y; Ling Y
    Bioorg Chem; 2023 May; 134():106479. PubMed ID: 36989958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
    Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 4-(4-aminophenyl)-6-phenylisoxazolo[3,4-b]pyridine-3-amine derivatives as novel FLT3 covalent inhibitors for the intervention of acute myeloid leukemia.
    Wang QX; Wang YB; Sha JK; Zhou H; Liu JC; Wu JZ; Tong ZJ; Cai J; Chen ZJ; Zhang CQ; Zheng XR; Wang JJ; Wang XL; Xue X; Yu YC; Ding N; Leng XJ; Dai WC; Sun SL; Chang L; Li NG; Shi ZH
    Drug Dev Res; 2023 Apr; 84(2):296-311. PubMed ID: 36644989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.
    Yuan T; Qi B; Jiang Z; Dong W; Zhong L; Bai L; Tong R; Yu J; Shi J
    Eur J Med Chem; 2019 Sep; 178():468-483. PubMed ID: 31207462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of pyrido.[3,4-b]pyrazin-2(1H)-one derivatives as potent FLT3 inhibitors.
    Sun M; Wang C; Wang P; Ye Q; Zhou Y; Li J; Liu T
    Bioorg Med Chem; 2023 Feb; 79():117155. PubMed ID: 36638621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.
    Kim H; Lee C; Yang JS; Choi S; Park CH; Kang JS; Oh SJ; Yun J; Kim MH; Han G
    Eur J Med Chem; 2016 Sep; 120():74-85. PubMed ID: 27187860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
    Ma F; Liu P; Lei M; Liu J; Wang H; Zhao S; Hu L
    Eur J Med Chem; 2017 Feb; 127():72-86. PubMed ID: 28038328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways.
    Yu M; Fang ZX; Wang WW; Zhang Y; Bu ZL; Liu M; Xiao XH; Zhang ZL; Zhang XM; Cao Y; Wang YY; Lei H; Xu HZ; Wu YZ; Liu W; Wu YL
    Acta Pharmacol Sin; 2021 Apr; 42(4):604-612. PubMed ID: 32694757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1
    Zhi Y; Wang Z; Yao C; Li B; Heng H; Cai J; Xiang L; Wang Y; Lu T; Lu S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
    Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
    Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.